📣 VC round data is live. Check it out!

JD Health Valuation Multiples

Discover JD Health's revenue and EBITDA valuation multiples and investment history, alongside public comparables like LY Corporation, BrightSpring Health, Dr. Sulaiman Al Habib, Rakuten and more.

JD Health Overview

About JD Health

JD Health is the largest healthcare e-commerce platform in China in terms of revenue. The company offers pharmaceutical drugs and healthcare products on its platform, both as a marketplace that connects merchants to consumers and as a first-party, or 1P, direct retailer. It also offers online consultation from real life doctors and separately partners with offline pharmacies that can provide location-based 24/7 delivery as part of an omnichannel initiative to complement its core e-commerce business. Its closest competitors are Alibaba Health and Meituan for its e-commerce business. As of Dec. 31, 2024, the platform has over 200 million active annual users and over 70,000 merchants. JD Health is 67.49% owned by its parent company, JD.com.


Founded

2018

HQ

China

Employees

3.6K

Financials (LTM)

Revenue: $12B
EBITDA: $746M

EV

$9B

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

JD Health Financials

JD Health reported last 12-month revenue of $12B and EBITDA of $746M.

In the same LTM period, JD Health generated $3B in gross profit, $746M in EBITDA, and $827M in net income.

Revenue (LTM)


JD Health P&L

In the most recent fiscal year, JD Health reported revenue of $11B and EBITDA of $934M.

JD Health is profitable as of last fiscal year, with gross margin of 25%, EBITDA margin of 9%, and net margin of 7%.

See analyst estimates for JD Health
LTMLast FY202320242025202620272028
Revenue$12B$11B$8B$9B$11B
Gross Profit$3B$3B$2B$2B$3B
Gross Margin25%25%22%23%25%
EBITDA$746M$934M$433M$742M$934M
EBITDA Margin6%9%5%9%9%
EBIT Margin6%6%1%3%5%
Net Profit$827M$794M$317M$615M$794M
Net Margin7%7%4%7%7%

Financial data powered by Morningstar, Inc.

JD Health Stock Performance

JD Health has current market cap of $16B, and enterprise value of $9B.

Market Cap Evolution


JD Health's stock price is $4.99.

JD Health share price increased by 1.9% in the last 30 days, and decreased by 9.0% in the last year.

JD Health has an EPS (earnings per share) of $0.25.

See more trading valuation data for JD Health
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$9B$16B1.9%1.9%-16.9%-9.0%$0.25

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

JD Health Valuation Multiples

JD Health trades at 0.8x EV/Revenue multiple, and 12.0x EV/EBITDA.

See NTM and 2027E valuation multiples for JD Health

EV / Revenue (LTM)


JD Health Financial Valuation Multiples

As of June 2, 2026, JD Health has market cap of $16B and EV of $9B.

JD Health has a P/E ratio of 19.3x.

LTMLast FY202320242025202620272028
EV/Revenue0.8x0.8x1.1x1.0x0.8x
EV/EBITDA12.0x9.6x20.6x12.0x9.6x
EV/EBIT12.7x13.9x86.2x40.8x15.3x
EV/Gross Profit3.1x3.3x5.1x4.5x3.3x
P/E19.3x20.1x50.4x25.9x20.1x
EV/FCF6.3x5.8x13.3x14.1x6.0x

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified JD Health Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

JD Health Margins & Growth Rates

JD Health grew revenue by 18% but EBITDA decreased by 12% in the last fiscal year.

In the most recent fiscal year, JD Health reported gross margin of 25%, EBITDA margin of 9%, and net margin of 7%.

See estimated margins and future growth rates for JD Health

JD Health Margins

Last FY202420252026202720282029
Gross Margin25%23%25%25%
EBITDA Margin9%9%9%6%
EBIT Margin6%3%5%6%
Net Margin7%7%7%7%
FCF Margin14%7%14%10%

JD Health Growth Rates

FY+1/FY23/2424/2525/2626/2727/2828/29
Revenue Growth18%9%26%18%
Gross Profit Growth21%12%37%21%
EBITDA Growth(12%)71%26%(12%)
EBIT Growth22%111%166%34%
Net Profit Growth13%94%29%13%
FCF Growth(18%)(5%)134%(15%)

Data powered by FactSet, Inc. and Morningstar, Inc.

JD Health Operational KPIs

JD Health's revenue per employee in the last FY averaged $3.0M, while opex per employee averaged $0.6M for the same period.

JD Health's Rule of 40 is 24% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

JD Health's Rule of X is 51% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Access forward-looking KPIs for JD Health
LTMLast FY202320242025202620272028
Rule of 4024%24%---
Bessemer Rule of X51%51%---
Revenue per Employee-$3.0M---
Opex per Employee-$0.6M---
S&M Expenses to Revenue5%5%5%5%5%
G&A Expenses to Revenue2%2%4%2%2%
R&D Expenses to Revenue2%2%2%2%2%
Opex to Revenue-19%21%20%19%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

JD Health Competitors

JD Health competitors include LY Corporation, BrightSpring Health, Dr. Sulaiman Al Habib, Rakuten, Wayfair, Lenskart, Chewy, Meesho, Nykaa and Sigma Healthcare.

Most JD Health public comparables operate across Consumer E-commerce, Pharmacies, Vertical E-commerce and HealthTech.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
LY Corporation2.0x1.8x8.8x7.4x
BrightSpring Health1.0x1.0x21.8x19.2x
Dr. Sulaiman Al Habib6.1x5.8x23.6x24.0x
Rakuten0.9x0.9x5.0x4.7x
Wayfair1.0x1.0x16.4x15.6x
Lenskart10.0x9.5x46.6x47.1x
Chewy0.7x0.7x12.2x11.1x
Meesho6.1x5.8x(67.2x)(60.4x)

This data is available for Pro users. Sign up to see all JD Health competitors and their valuation data.

Start Free Trial

JD Health VC Funding History

Before going public, JD Health raised $2B in total equity funding, across 2 rounds.

Last private valuation of JD Health was $7B, after raising $1B in May 2019 from BPEA EQT, CICC, CPE, and 2 other investors.


JD Health Funding Rounds

DateStageRaised FromRaisedValuationRev. MultipleDeal Summary
Aug-20Series BHillhouse Investment; Kun Ling Capital$830M-JD Health, the healthcare arm of JD.com providing pharmacy delivery, telemedicine, and health services, raised over $830 million in a Series B round from Hillhouse Capital in August 2020, expected to close in Q3. This followed a $1 billion Series A in 2019 at a $6.9-7 billion valuation. JD.com remained the majority shareholder post-deal. The investment aimed to strengthen JD Health's pharmacy supply chain and expand healthcare services amid COVID-19-driven growth in online consultations and drug delivery. The company reported 190 million annual active consumers for its online drugstore as of May 2020 and over 1.7 million patients using diagnosis services since the outbreak, but achieved profitability without specified revenue or EBITDA figures. Hillhouse, an early JD.com investor, led this round matching the query details, positioning JD Health as a unicorn with rapid scaling in China's digital health market.
May-19Series ABPEA EQT; CICC; CPE; JD.com; Mubadala Capital Ventures$1B$7B-

Investments by JD Health

JD Health has invested in 1 company to date.

Latest investment by JD Health was on August 4th 2021. JD Health invested in Jiangxi Rimag Group in their $93M Series D round (EV/Revenue multiple available to Pro users).

See VC round multiples

Latest Investments by JD Health

Jiangxi Rimag Group
Description
Jiangxi Rimag Group Co Ltd is a medical group specializing in medical imaging in China. the company generates revenue mainly through the following medical imaging services and solutions: Imaging Center Services, Imaging Solution Services, and Rimag Cloud Services. The Imaging Center Services include examination and diagnostic services to patients and other healthcare consumers via its flagship imaging centers, such as MRI, CT, PET, X-ray, ultrasound and mammography. Majority of the revenue comes from Imaging center services.
HQ CountryChina
HQ City
Beijing
Deal Date4 Aug 2021
RoundSeries D
Raised$93M
InvestorsJD Health; Neovision Capital; OrbiMed; Tiefa Capital; Tongfu Fund
Valuationundisclosed
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all JD Health investments and their VC round multiples.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About JD Health

When was JD Health founded?JD Health was founded in 2018.
Where is JD Health headquartered?JD Health is headquartered in China.
How many employees does JD Health have?As of today, JD Health has over 3K employees.
Who is the CEO of JD Health?JD Health's CEO is Enlin Jin.
Is JD Health publicly listed?Yes, JD Health is a public company listed on HKEX.
What is the stock symbol of JD Health?JD Health trades under 06618 ticker.
When did JD Health go public?JD Health went public in 2020.
Who are competitors of JD Health?JD Health main competitors include LY Corporation, BrightSpring Health, Dr. Sulaiman Al Habib, Rakuten, Wayfair, Lenskart, Chewy, Meesho, Nykaa, Sigma Healthcare.
What is the current market cap of JD Health?JD Health's current market cap is $16B.
What is the current revenue of JD Health?JD Health's last 12 months revenue is $12B.
What is the current revenue growth of JD Health?JD Health revenue growth (NTM/LTM) is 18%.
What is the current EV/Revenue multiple of JD Health?Current revenue multiple of JD Health is 0.8x.
What is the current EBITDA of JD Health?JD Health's last 12 months EBITDA is $746M.
What is JD Health's EBITDA margin?JD Health's last 12 months EBITDA margin is 6%.
What is the current EV/EBITDA multiple of JD Health?Current EBITDA multiple of JD Health is 12.0x.
What is the current FCF of JD Health?JD Health's last 12 months FCF is $1B.
What is JD Health's FCF margin?JD Health's last 12 months FCF margin is 12%.
What is the current EV/FCF multiple of JD Health?Current FCF multiple of JD Health is 6.3x.
How many companies JD Health has acquired to date?JD Health hasn't acquired any companies yet (or none have been disclosed publicly).
In how many companies JD Health has invested to date?As of June 2026, JD Health has invested in 1 company.
What was the last JD Health investment?On 4th August 2021 JD Health invested in Jiangxi Rimag Group, participating in a $93M Series D round, alongside Neovision Capital, OrbiMed, Tiefa Capital, and Tongfu Fund.
In what companies JD Health invested in?JD Health invested in Jiangxi Rimag Group.

See public comps similar to JD Health

Lists including JD Health

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial